Edition:
India

Biocon Ltd (BION.NS)

BION.NS on National Stock Exchange of India

668.00INR
19 Sep 2018
Change (% chg)

-- (--)
Prev Close
Rs668.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,473,072
52-wk High
Rs696.60
52-wk Low
Rs328.00

Summary

Name Age Since Current Position

Kiran Mazumdar-Shaw

65 Executive Non-Independent Chairman of the Board, Managing Director

Arun Chandavarkar

53 2014 Chief Executive Officer, Joint Managing Director, Executive Director

John Shaw

68 2017 Non-Executive Vice Chairman of the Board

Siddharth Mittal

2014 Chief Financial Officer

Peter Bains

59 CEO & Director of Syngene

Abhijit Barve

2010 President - Research & Development

Ravindra Limaye

2014 President - Marketing

Amitava Saha

2013 Senior Vice President - Human Resources

Satish S.S.

2018 Company Secretary and Compliance Officer

Akhilesh Nand

2018 Interim Chief Compliance Officer

Catherine Rosenberg

54 Director of Syngene

Ravi Mazumdar

60 Non-Executive Non-Independent Director

M. Damodaran

2016 Additional Independent Director

Vijay Kuchroo

61 2015 Additional Independent Director

Jeremy Levin

65 2015 Additional Independent Director

Bobby Parikh

54 2018 Independent Director

Daniel Bradbury

56 2013 Non-Executive Independent Director

Mary Harney

62 2012 Non-Executive Independent Director

Russell Walls

72 2011 Non-Executive Independent Director

Saurabh Paliwal

Head - Investor Relations

Biographies

Name Description

Kiran Mazumdar-Shaw

Dr. Kiran Mazumdar-Shaw is Executive Non-Independent Chairman of the Board, Managing Director of Biocon Limited. She is a first generation entrepreneur with more than 38 years’ experience in the field of biotechnology. After graduating in B.Sc. (Zoology Hons.) from Bangalore University in 1973, she completed her post-graduate degree in malting and brewing from Ballarat College, Melbourne University in 1975. She has been awarded with several honorary degrees including Honorary Doctorate of Science from Ballarat University, in recognition of pre-eminent contribution to the field of Biotechnology, 2004, Doctor of Technology from the University of Abertay Dundee, 2007, Doctor of Science from the University of Glasgow, 2008 and Doctor of Science from the Heriot-Watt University, Edinburgh, 2008. She is a founder promoter and has led the Company since its inception in 1978. She is the recipient of several awards, the most noteworthy being the ‘Padmabhushan’ Award (one of the highest civilian awards in India) in 2005 conferred by the President of India, the Nikkei Asia Prize, 2009 for Regional Growth, Express Pharmaceutical Leadership Summit Award 2009 for Dynamic Entrepreneur, the Economic Times ‘Businesswoman of the Year’, the ‘Veuve Clicquot Initiative for Economic Development For Asia, Ernst & Young’s Entrepreneur of the Year Award for Life Sciences & Healthcare, ‘Technology Pioneer’ recognition by World Economic Forum and The Indian Chamber of Commerce Lifetime Achievement Award. She heads several biotechnology task forces including the Karnataka Vision Group on Biotechnology, an initiative by the Government of Karnataka and the National Taskforce on Biotechnology for the Confederation of Indian Industry (CII). She is also a member of the Prime Minister’s Council on Trade and Industry and is a Member of the Governing Body and General Body of the Indian Pharmacopoeia Commission, an autonomous body of the Government of India.

Arun Chandavarkar

Dr. Arun Suresh Chandavarkar, Ph.D., is Chief Executive Officer, Joint Managing Director, Executive Director of Biocon Limited. He is one of India’s bio-pharmaceuticals companies with a therapeutic focus in the areas of diabetes, oncology and cardiovascular disease. Biocon’s subsidiaries, Syngene and Clinigene, are India’s providers of custom research and clinical research services respectively. Dr. Chandavarkar completed his B Tech. in Chemical Engineering from the Indian Institute of Technology, Mumbai in 1984, and was awarded a Ph.D. in BioChemical Engineering from the Massachusetts Institute of Technology, Cambridge, USA in 1990. He joined Biocon as General Manager – Operations in 1990 and subsequently took on the role of President – Operations & Technology. Under his Biocon established at scale in diverse technology platforms spanning microbial fermentation, cell culture, chemical synthesis and purification to address a wide portfolio of products from specialty enzymes to active pharmaceutical ingredients to recombinant therapeutic proteins. His current responsibilities cover all aspects of Biocon’s business with a specific emphasis on strategic management.

John Shaw

Mr. John Mccallum Marshall Shaw serves as Non-Executive Vice Chairman of the Board of the Company. He was Executive Non-Independent Vice Chairman of the Board, Whole-time Director of Biocon Limited. He is a foreign promoter and a Whole-time Director of the Company. He is also a controlling shareholder and director of Glentec International. He completed his M.A. (Economic Hons.) in History and Political Economy from Glasgow University, U.K. in 1970. He had 27 years’ experience with Coats Viyella plc. in various capacities including finance and general administration and also served as Finance Director and Managing Director of Coats Viyella group companies in various locations around the world, before he came on the Board of Biocon Limited in 1999.

Siddharth Mittal

Peter Bains

Mr. Peter Bains is CEO & Director of Syngene., a subsidiary of the company. He is Director of Sosei, a Tokyo-listed Japanese biotechnology company; Extensive track record of achievement as a senior pharma and life sciences executive; Non- Executive Chairman, Fermenta Biotech Ltd. and Director and Member of Audit Committee, Kromek Group Plc.

Abhijit Barve

Dr. Abhijit Barve, M.D. Ph.D. is President - Research & Development of Biocon Limited. He joined the Biocon in 2010.

Ravindra Limaye

Amitava Saha

Satish S.S.

Mr. Satish Kumar S.S. is Company Secretary and Compliance Officer of the Company. He is an associate member of The Institute of Company Secretaries of India, and brings with him over fifteen years of diverse experience across Secretarial, Legal and Investor Relations functions. Prior to joining Biocon Limited, he was working as Assistant General Manager Compliance & Assistant Company Secretary with Himatsingka Seide Limited, Bangalore.

Akhilesh Nand

Catherine Rosenberg

Professor Catherine Rosenberg is Director of Syngene, a subsidiary of company. University Research Chair Professor and Chairman, Department of Electrical and Computer Engineering, University of Waterloo, Canada.

Ravi Mazumdar

Professor Ravi Mazumdar, Ph.D., is Non-Executive Non-Independent Director of Biocon Limited. He was educated at IIT, Bombay (B.Tech in Electrical Engineering, 1977), and received the MSc,DIC from Imperial College, London (1978) and a PhD from the University of California, Los Angeles (UCLA) in 1983. He is currently a University Research Chair Professor at University of Waterloo, Canada. Prior to this he was a faculty member at Purdue University, U.S.A, Columbia University, U.S.A., University of Essex, U.K. He has held visiting positions at the Indian Institute of Science, Bangalore; the University of California, Berkeley and Telecom-Paris Tech, France. He is currently a J.D. Gandhi Distinguished Visiting Professor at the Indian Institute of Technology, Bombay. He has over 150 referred publications in the area of high speed communication networks, applied probability and stochastic processes, and in statistical signal processing. He has been a member of several advisory committees and working groups, including the US Congress Sub-Committee on Science and Technology. He is a Fellow of the Royal Statistical Society and Fellow of the Institute of Electrical and Electronics Engineers, Inc.

M. Damodaran

Vijay Kuchroo

Dr. Vijay K Kuchroo is Additional Independent Director of the company. He is Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women’s Hospital, and Co-Director of the Center for Infection and Immunity, Brigham Research Institutes, Boston. He is also an associate member of the Broad Institute and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation. He is also the Director of the newly formed Evergrande Centre for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital. To his credit, Dr. Kuchroo first described the inhibitory receptor TIM-3, which is being exploited as a target for cancer immunotherapy. He was first to describe the development of highly pathogenic Th17 cells, which has been shown to induce multiple different autoimmune diseases in humans. He has published over 325 original research papers in the field of Immunology and a paper describing development of Th17 authored by him has been one of the highest cited papers in Immunology. In addition, he has 25 patents and has founded 5 different biotech companies including CoStim Pharmaceuticals and Tempero Pharmaceuticals. He also serves on the scientific advisory boards and works in advisory capacity to a number of big pharmaceutical companies including Pfizer, Novartis and Glaxo-Smith-Kline (GSK).

Jeremy Levin

Dr. Jeremy M Levin is Additional Independent Director of the company. He holds a Bachelor’s Degree in Zoology and a Masters of Arts and a Doctorate in the structure of Chromatin from the University of Oxford. In addition he received degrees of Bachelor of Medicine and Bachelor of Surgery from the University of Cambridge. He is Chairman and CEO of Ovid Therapeutics, Inc. a private company developing novel medicines for orphan diseases of the brain. Prior to Ovid, he worked as President and CEO of Teva Pharmaceutical Industries Ltd. where he was responsible for overseeing all aspects of one of the world’s largest pharmaceutical companies. He has also served as a member of the executive committee of Bristol-Myers Squibb and as a senior executive in Novartis AG. He is the recipient of a number of awards including the Kermode Prize for work on novel hypertension drugs, the Albert Einstein Award for Leadership in Life Sciences, the B’nai B’rith Award for Distinguished Achievement and the Officer’s Cross of the Order of Merit of the Republic of Hungary.

Bobby Parikh

Mr. Bobby Kanubhai Parikh serves as Independent Director of the Company. Mr. Parikh is the Founder of Bobby Parikh Associates, a boutique firm focused on providing strategic tax and regulatory advisory services. Mr. Parikh's particular area of focus is providing tax and regulatory advice in relation to transactions and other forms of business reorganizations, whether inbound, outbound or wholly domestic. In this regard, Mr. Parikh works extensively with private equity funds, other institutional investors and owners and managers of businesses to develop bespoke solutions that optimally address the commercial objectives underpinning a particular transaction or a business reorganization. Mr. Parikh also works closely with regulators and policy formulators, in providing inputs to aid in the development of new regulations and policies, and in assessing the implications and efficacy of these and providing feedback for action. Mr. Parikh was most recently co-founder of BMR Advisors, a highly regarded tax and transactions firm which he helped establish and run for over 12 years. Formerly Chief Executive Officer of Ernst & Young in India and Country Managing Partner of Arthur Andersen, Mr. Parikh has been a member of a number of trade and business associations, as well as a member of the advisory or executive boards of nongovernmental, not-for-profit organizations and private as well as listed Indian companies. He is a graduate in Commerce from the University of Mumbai and qualified as a Chartered Accountant from the Institute of Chartered Accountants of India in 1987.

Daniel Bradbury

Mr. Daniel M. Bradbury is Non-Executive Independent Director of Biocon Ltd. He is Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment Firm, Life Sciences Executive with over 30 years of experience in creating and implementing strategies that transform businesses, bring novel medicines to market, Former President, Chief Executive Officer and Director of Amylin, On the board of trustees of the Keck Graduate Institute, California, USA, Member of San Diego’s Rady School of Management’s Advisory Council, Member of Miami’s Innovation Corporate Advisory Council.

Mary Harney

Ms. Mary Harney is Non-Executive Independent Director of Biocon Limited., since April 26, 2012. She was a member of the Irish Parliament for over thirty years and was a Government Minister for seventeen years in Environment, Economic and in Health Ministries. She was Deputy Prime Minister for over nine years. She is an economics graduate of Trinity College Dublin. She was the longest serving woman ever in the Irish Parliament and in 1993 became the only woman to have led a political party in Ireland. She retired from politics in January 2011 and is now involved in business. She is a director of several technology companies as well as an insurance company in Ireland. She is a member of the Board of CRANN Trinity College Dublin’s largest research institute and is chair of AMBER, the Advanced Materials and Bio-Engineering Research Centre at Trinity, a joint research enterprise with University College Cork, the Royal College of Surgeons in Ireland and industry. She is on the board of the Hospice Foundation of Ireland and is an honorary member of the International Women’s Forum.

Russell Walls

Mr. Russell Walls is Non-Executive Independent Director of Biocon Limited., since April 28, 2011. He is a Fellow Member of the Association of Chartered Certified Accountants, U.K and brings to the Board his extensive experience in the field of finance. He possesses experience as director across a range of industries such as pharmaceuticals, textiles, transport and leisure. He is currently Chairman of Aviva Insurance Limited and on Board of Mytrah Energy Limited and Signet Jewelers Limited.

Saurabh Paliwal